FDA Resignation
“Key FDA Aide in Rezulin Case Resigns” (Oct. 18), on the resignation of Dr. Murray Lumpkin, did a major disservice to the Food and Drug Administration and, more important, Dr. Lumpkin. He resigned for personal reasons alone, and the FDA respects his right to privacy as a career, nonpolitical employee.
The FDA’s handling of Rezulin has been a matter of public record. The FDA convened three public advisory committee meetings and followed the committee’s advice. All actions on this product were discussed and supported at the highest levels of the FDA.
The American people have been well served by Lumpkin’s dedication to the public health.
LINDA A. SUYDAM
Senior Associate Commissioner
FDA, Rockville, Md.
Start your day right
Sign up for Essential California for news, features and recommendations from the L.A. Times and beyond in your inbox six days a week.
You may occasionally receive promotional content from the Los Angeles Times.
